Your session is about to expire
← Back to Search
Combination Therapy + BPA for Thromboembolic Pulmonary Hypertension (EPIPHANY Trial)
EPIPHANY Trial Summary
This trial is testing a new combination therapy for inoperable or residual Chronic Thromboembolic Pulmonary Hypertension (CTEPH). The therapy consists of two drugs, Riociguat and Macitentan, and balloon pulmonary angioplasty (BPA). The goal is to see if this new therapy can improve RV function and hemodynamics.
EPIPHANY Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowEPIPHANY Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.EPIPHANY Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I cannot take riociguat or macitentan due to adverse reactions.I have severe liver disease.My cancer is currently active.I have been diagnosed with sarcoidosis.I am not eligible for pulmonary thromboendarterectomy.I have sickle cell anemia.I am 18 years old or older.My heart function is reduced (LVEF < 45%) or I have severe thickening of my heart walls.I have been diagnosed with chronic thromboembolic pulmonary hypertension.I have not started treatment for CTEPH/PAH but plan to, including BPA.My body and disease level are right for balloon pulmonary angioplasty.
- Group 1: participants with inoperable CTEPH
- Group 2: post PTE residual CTEPH
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has this clinical trial been conducted before?
"As of right now, there are 16 different ongoing trials for post PTE residual CTEPH in 131 cities and 47 countries. The first study was completed back in 2008 and only involved 22 patients. However, since then, 57 more studies have been conducted."
How many people are being enrolled in this clinical trial?
"Unfortunately, this particular study is not enrolling patients at the moment. The listing was originally created on January 1st 2023 but was edited last on October 5th, 2022. However, there are other options; 19 studies for people with chronic thromboembolic pulmonary hypertension (cteph) and 16 studies for post PTE residual CTEPH are still admitting patients."
Are there serious dangers associated with post PTE residual CTEPH?
"Given that this is a Phase 3 trial with some efficacy data as well as multiple reports on safety, the Power team rated post PTE residual CTEPH's safety at a level 3."
Have other studies been conducted that focus on post PTE residual CTEPH?
"At the moment, there are 16 clinical trials researching post PTE residual CTEPH. A third of those active studies are in their final Phase 3 stage. The majority of research for this treatment is conducted in Krakow and Lazio; however, there are 938 total research sites worldwide."
Are we currently enrolling patients for this experiment?
"No, this particular clinical study is not admitting any more patients at the moment. This trial was first posted on 1/1/2023 and edited for the last time on 10/5/2022. If you're looking for other cteph trials, there are 19 studies still recruiting and 16 post PTE residual CTEPH studies that are actively seeking participants.."
Share this study with friends
Copy Link
Messenger